The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 14, 2020

Filed:

May. 08, 2018
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Steven L. Colletti, Princeton Junction, NJ (US);

Thomas J. Tucker, North Wales, PA (US);

David M. Tellers, Lansdale, PA (US);

Boyoung Kim, Natick, MA (US);

Rob Burke, Encinitas, CA (US);

Kathleen B. Calati, Saline, MI (US);

Matthew G. Stanton, Needham, MA (US);

Rubina G. Parmar, Acton, MA (US);

Jeffrey G. Aaronson, San Francisco, CA (US);

Weimin Wang, Churchville, PA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/87 (2006.01); A61K 31/713 (2006.01); A61K 38/10 (2006.01); A61K 38/16 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 31/7125 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7125 (2013.01); A61K 31/713 (2013.01); A61K 38/10 (2013.01); A61K 38/16 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/87 (2013.01); C07K 2319/10 (2013.01); C12N 2310/14 (2013.01); C12N 2310/351 (2013.01); C12N 2320/31 (2013.01);
Abstract

Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)-(G); wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)-(L)-(G); wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.


Find Patent Forward Citations

Loading…